Laleh Majlessi

List of Publications by Year
in descending order

30 papers	2,857 citations	313897 21 h-index	445597 30 g-index
36 all docs	36 docs citations	36 times ranked	3368 citing authors

#	Article	IF	Citations
1	Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Medicine, 2003, 9, 533-539.	30.1	576
2	ESX secretion systems: mycobacterial evolution to counter host immunity. Nature Reviews Microbiology, 2016, 14, 677-691.	29.2	322
3	Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence. Infection and Immunity, 2006, 74, 88-98.	2.4	286
4	Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP. PLoS Pathogens, 2008, 4, e33.	4.1	238
5	Disruption of the ESXâ€5 system of <i>Mycobacterium tuberculosis</i> causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Molecular Microbiology, 2012, 83, 1195-1209.	2.5	180
6	Functional Analysis of Early Secreted Antigenic Target-6, the Dominant T-cell Antigen of Mycobacterium tuberculosis, Reveals Key Residues Involved in Secretion, Complex Formation, Virulence, and Immunogenicity. Journal of Biological Chemistry, 2005, 280, 33953-33959.	3.5	140
7	Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host and Microbe, 2021, 29, 236-249.e6.	11.0	115
8	Strong Immunogenicity and Cross-Reactivity of Mycobacterium tuberculosis ESX-5 Type VII Secretion -Encoded PE-PPE Proteins Predicts Vaccine Potential. Cell Host and Microbe, 2012, 11, 352-363.	11.0	103
9	Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Reports, 2017, 18, 2752-2765.	6.3	102
10	An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis. Infection and Immunity, 2006, 74, 2128-2137.	2.4	95
11	High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection. Infection and Immunity, 2006, 74, 3396-3407.	2.4	88
12	Release of mycobacterial antigens. Immunological Reviews, 2015, 264, 25-45.	6.1	82
13	Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Scientific Reports, 2017, 7, 5390.	3.4	76
14	CD8 + -T-CellResponses of Mycobacterium-Infected Mice to a Newly Identified MajorHistocompatibility Complex Class I-Restricted Epitope Shared byProteins of the ESAT-6Family. Infection and Immunity, 2003, 71, 7173-7177.	2.4	52
15	Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. Genome Biology and Evolution, 2018, 10, 1858-1874.	2.6	51
16	CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005770.	4.1	50
17	Intrinsic Antibacterial Activity of Nanoparticles Made of Î²-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. ACS Nano, 2019, 13, 3992-4007.	15.3	46
18	RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection. PLoS Pathogens, 2018, 14, e1007139.	4.1	39

#	Article	IF	Citations
19	Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. Cell Reports, 2018, 23, 1072-1084.	6.3	30
20	Brain crossâ€protection against SARSâ€CoVâ€2 variants by a lentiviral vaccine in new transgenic mice. EMBO Molecular Medicine, 2021, 13, e14459.	7.3	27
21	Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. Cellular Microbiology, 2016, 18, 1070-1077.	2.3	26
22	Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections. Particle and Particle Systems Characterization, 2019, 36, 1800360.	2.5	24
23	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Communications Biology, 2021, 4, 713.	4.5	21
24	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy, 2022, 30, 2984-2997.	8.1	20
25	Use of lentiviral vectors in vaccination. Expert Review of Vaccines, 2021, 20, 1571-1586.	4.5	19
26	Ecto-5â€²-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment. Infection and Immunity, 2015, 83, 3666-3674.	2.4	16
27	A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ TÂcell immunity. Cell Reports, 2022, 40, 111142.	6.3	9
28	Un candidat vaccin lentiviral anti-Covid-19 administrable par voie intranasale. Medecine/Sciences, 2021, 37, 1172-1175.	0.2	4
29	Full eradication of preâ€clinical human <scp>papillomaÂvirusâ€induced</scp> tumors by a lentiviral vaccine. EMBO Molecular Medicine, 2023, 15, .	7.3	3
30	Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters. Vaccines, 2023, 11, 12.	4.5	1